Novel CD40:CD154 binding interruptor compounds and use thereof to treat immunological complications
申请人:Zheng Zhongli
公开号:US20070249682A1
公开(公告)日:2007-10-25
The present invention relates to novel CD40:CD154 binding interrupter compounds and use of these compounds and pharmaceutical compositions comprising them, to treat conditions associated with inappropriate CD154 activation in a subject. Specifically, this invention provides compounds which are identified by screening a library of small molecules for those that are capable of specifically binding CD154 and interrupting CD40:CD154 interaction.
本发明涉及新型CD40:CD154结合中断化合物的使用以及包含这些化合物的制药组合物,用于治疗与主体中不适当的CD154激活有关的疾病。具体而言,本发明提供了通过筛选小分子库以鉴定能够特异性结合CD154并中断CD40:CD154相互作用的化合物。